March 29, 2017 /

Akashi Provides Update on HT-100 (March 2017)

Parent Project Muscular Dystrophy by: Parent Project Muscular Dystrophy

Akashi Provides Update on HT-100 (March 2017)

Parent Project Muscular Dystrophy and Akashi Therapeutics hosted a webinar on March 27, 2017 to discuss HT-100 and next steps for the clinical program. Akashi CEO Marc Blaustein presented data from the previous clinical program of HT-100, discussed FDA’s recent decision to allow the clinical development of HT-100 to resume, and answered questions from the community.

Research & Clinical Trial Webinars,
Webinars

Join Our Mailing List

This field is for validation purposes and should be left unchanged.
BBB Accredited Charity logoCharity Navigator Four Star Charity logoNational Health Council Standards of Excellence Certification Program logo